Genmab A/S (GMAB) to Release Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Genmab A/S to post earnings of $0.15 per share and revenue of $905.7740 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.41). The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Genmab A/S Stock Up 0.9%

Genmab A/S stock traded up $0.24 during trading hours on Wednesday, hitting $27.76. The company had a trading volume of 186,004 shares, compared to its average volume of 1,678,761. Genmab A/S has a fifty-two week low of $18.89 and a fifty-two week high of $35.43. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The firm has a market capitalization of $17.31 billion, a P/E ratio of 17.90, a price-to-earnings-growth ratio of 1.20 and a beta of 0.86. The firm’s fifty day moving average is $27.39 and its 200-day moving average is $29.99.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Wolfe Research assumed coverage on Genmab A/S in a report on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective on the stock. Morgan Stanley assumed coverage on shares of Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price for the company. HC Wainwright decreased their target price on shares of Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Finally, Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $39.07.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC boosted its stake in Genmab A/S by 11.3% in the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after buying an additional 419 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the period. Orion Porfolio Solutions LLC boosted its stake in shares of Genmab A/S by 2.3% in the 3rd quarter. Orion Porfolio Solutions LLC now owns 19,693 shares of the company’s stock valued at $604,000 after purchasing an additional 441 shares in the last quarter. Captrust Financial Advisors grew its holdings in shares of Genmab A/S by 2.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock worth $464,000 after purchasing an additional 526 shares during the last quarter. Finally, CIBC Private Wealth Group LLC lifted its holdings in Genmab A/S by 291.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.